Fecal calprotectin (fCAL) is a biomarker used for disease monitoring in patients suffering from intestinal bowel disease (IBD) since it correlates closely with mucosal healing. Calprotectin measuring requires patients to collect and return stool samples resulting in relatively low return rate of samples. Home-based fCAL testing may improve adherence. In this post three recent publications
- support@ibdoc.net
- +41 61 487 12 12
- www.buhlmannlabs.ch
Blog Archives
Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN’s UK distributor Alpha Laboratories Highlight the Article: “In the six months that we have been working with the IBDoc®, one patient was saved from hospital admission. It looked like they were having an IBD flare but the symptoms were actually
At this year’s SwissMedtech Day, BÜHLMANN was nominated to receive the Swiss Medtech Award. Switzerland is listed by key rankings as the “globally most innovative country”. Medtech one of the industries heavily contributing to this ranking. Out of 25 applications BÜHLMANN Laboratories AG was chosen to present IBDoc® to a Jury of medtech and academic
Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video:
Tactio Health Group and Telia Company team up to accelerate the development of patient-centred digital health programs in Sweden and other Nordic and Baltic countries. The Swedish telecommunication company Telia, together with AbbVie Sweden, developed the IBD Home platform using the TactioRPM platform. IBD Home is a complete IBD remote monitoring ecosystem. The IBD Home app
Read a recent post from Amanda Appleton, the Product Manager for Calprotectin at our UK distributor Alpha Laboratories. She ends the article with following sentence: “App technology has the ability not only to improve the health of patients but to save money through rapid optimisation of treatment, enable early interventions through monitoring before conditions get
On 4th December 2017 the National Institute for Health and Care Excellence issued a Medtech Innovation Briefing [MIB132]: ‘Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease’. This describes the innovative aspect that test results can be acted on more quickly than waiting for standard laboratory tests and could help reduce colonoscopies and clinical appointments. Costs may
A patient from the UK is currently testing IBDoc® and is writing about his experience on his blog. He started the test last October and is trying this new tool to monitor his Crohn’s Disease during one year. Have a look at his blog posts here
For the second year, Boussias Communications and Health Daily organized the Healthcare Business Awards 2017 in Greece. The award is meant to showcase and reward innovative healthcare actions. This year the AbbVie Greece received the Gold Award in the Health Innovation category. Together with BÜHLMANN Laboratories AG and the home care provider PCC Hellas AbbVie implemented IBDoc® into their Care Programm for patients suffering
In September we received regulatory approval to expand the list of supported smartphones for IBDoc®. Like for the previous approvals, we used our established thorough validation control to add 12 additional models. Since each smartphone model differs in camera and processor type, which relates to differences in measurement we always need to make sure that the supported